Pharmaceuticals company Windlas Biotech announced Q3FY25 results Revenue from operations stood at Rs 195.0 crore as against Rs 162.2 crore, a growth of 20.2% YoY. EBITDA stood at Rs 24.6 crore as against Rs 20.3 crore YoY, a growth of 21.1% YoY. EBITDA Margin (%) came in at 12.6%. PAT stood at Rs 15.6 crore as against Rs 15.1 crore YoY, a growth of 3.2% YoY. PAT Margin (%) came in at 8.0%. Hitesh Windlass, Managing Director – Windlas Biotech said, “The Indian Pharmaceutical Market (IPM) registered a 7% year-on-year growth in Q3FY25, primarily driven by price increases, as volume growth remained negative. We are pleased to report a resilient performance, as we have registered YoY revenue growth of 21% in 9M and 20% in Q3. This performance is driven by strong momentum in our Trade Generics and Institutional vertical, complemented by consistent contributions from our CDMO and Export verticals. The growth of the business development team, expanded customer base and the introduction of new products are driving positive results in the Generic Formulations CDMO vertical despite negative volume growth and API prices reduction resulting in lower conversion. The Trade Generics and Institutional vertical continues to maintain strong growth trajectory. Our sales force has been broadened across both key and surrounding territories for this vertical, enhancing our market reach. In January 2025, the injectables facility received Good Manufacturing Practices (GMP) certification from the Food Safety & Drugs Administration Authority of Uttarakhand, following an inspection in December 2024, confirming compliance with WHO’s TRS Guidelines in all five plants of the company. Accordingly large customers have scheduled audits of our Injectable facility in Q4FY25. Stability testing completion of production batches taken in H1FY25 has commenced in Q3FY25. In line with our strategic roadmap, the Plant-2 extension is now fully operational.” Komal Gupta, CEO & CFO - Windlas Biotech said, “Our all-time high revenue streak persists into the 8th quarter. For 9MFY25, revenue reached Rs 557.2 crore showcasing 21% YoY growth and Q3FY25 revenue rose by 20% YoY to Rs 195.0 crore. We are committed to enhancing our capabilities, expanding into new regions and providing high-quality pharmaceutical products that address the evolving needs of our customers and patients. Our strategic initiatives and operational efficiencies position us for long-term growth and value creation. Our diversified product portfolio, strong customer relationships, and dedicated team, combined with strategic investments position us for consistent growth in our Generic Formulation CDMO vertical. This vertical recorded a 15% YoY increase in 9MFY25 to Rs 407.9 crore. For Q3FY25, this vertical generated Rs 135.7 crore in revenue, witnessing an 8% YoY growth. Our Trade Generics and Institutional vertical continues its growth momentum, indicating strong market acceptance of the company’s product offerings. In 9MFY25, revenue surged to Rs 126.6 crore, marking a 44% YoY increase. For Q3FY25, revenue increased to Rs 49.6 crore, registering an 74% growth YoY. Our exports vertical reported revenue of Rs 22.6 crore in 9MFY25, a 23% increase YoY, with Q3FY25 showing a revenue of Rs 9.7 crore reflecting 19% growth YoY. EBITDA surged by 22% YoY to Rs 68.6 crore (12.3% margin) for 9MFY25 and by 21% YoY to Rs 24.6 crore (12.6% margin) for Q3FY25. Despite increase in depreciation by Rs 9.7 crore for 9MFY25 and 3.6 crore for Q3FY25 - almost entirely due to injectable facility; PAT stood at Rs 44.7 crore - up 9% for 9MFY25 YoY and Rs 15.6 crore, up 3% YoY for Q3FY25.” Result PDF